How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma

Area of Science:

• Hematologic Malignancies
• Immunology
• Oncology

Background:

• Multiple myeloma (MM) progression involves immune system dysfunction, particularly affecting T-cells.
• Despite treatment advances, MM remains largely incurable, highlighting the need for novel therapeutic strategies.
• The immunosuppressive tumor microenvironment in MM poses a significant challenge to effective treatment.

Purpose of the Study:

• To review T-cell alterations during multiple myeloma evolution.
• To provide an overview of T-cell-dependent immuno-oncology approaches for MM.
• To explore the potential of these therapies across the MM disease continuum.

Main Methods:

• Review of scientific literature on T-cell dynamics in multiple myeloma.
• Analysis of current and emerging T-cell-dependent immuno-oncology strategies.
• Examination of clinical data for therapies such as CAR T-cells and bispecific antibodies.

Main Results:

• T-cell dysfunction is a hallmark of multiple myeloma progression.
• T-cell-dependent immunotherapies, including chimeric antigen receptor (CAR) T-cells and bispecific antibodies, demonstrate significant clinical activity, particularly in relapsed/refractory MM.
• B-cell maturation antigen (BCMA)-targeted CAR T-cells and bispecific antibodies have shown promising deep responses.

Conclusions:

• Understanding T-cell roles in MM is crucial for optimizing immunotherapy.
• Immuno-oncology strategies targeting T-cells offer new hope for patients with multiple myeloma.
• Further research into the immune-MM interplay may enhance therapeutic efficacy across all disease stages.